Prostate-specific antigen promoter and probasin promoter transcriptional machinery (null)

The prostate-specific antigen (PSA) promoter is a regulatory DNA sequence upstream of the PSA (KLK3) gene that binds transcription factors and the androgen receptor, enabling tissue-specific, androgen-dependent gene expression in prostate epithelial cells[1][3][5][7]. The probasin (PB) promoter, derived from rat, is similarly regulated by androgens and provides highly prostate-specific gene expression in transgenic mouse models[4]. Both promoters contain cis-acting elements, including androgen response elements (AREs), forkhead binding sites (for FoxA1), and binding sites for other transcription factors (e.g., NFI, Oct-1, c-Jun), which together form a *transcriptional machinery* driving prostate-selective expression[4]. These promoters are often used in research and gene therapy to drive prostate-specific transgene expression, but are not themselves "therapeutic targets" in the sense of a druggable protein or receptor. Rather, *their functional importance lies in regulating the expression of genes critical for prostate function and pathology* (notably PSA in prostate cancer)[1][4][5][7]. **Note:** This entry is classified as "incorrect" as a drug target because promoters and their associated transcriptional machinery are not considered direct therapeutic targets like a receptor or enzyme, but are instead regulatory elements and complexes. If your intent is to study the androgen receptor (AR) or a specific protein component, those would represent proper molecular targets.

Other names

PSA promoter and PB promoter transcriptional complexprostate-restricted regulatory machineryandrogen-responsive promoter elements

Drugs that interact with the androgen receptor inhibit or prevent AR from binding to androgen response elements in the PSA or PB promoters, suppressing transcription of PSA or probasin genes[5].